148 related articles for article (PubMed ID: 25753327)
1. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings.
Rizvi H; Butler T; Calaminici M; Doobaree IU; Nandigam RC; Bennett D; Provan D; Newland AC
Br J Haematol; 2015 May; 169(4):590-4. PubMed ID: 25753327
[TBL] [Abstract][Full Text] [Related]
2. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.
Ghanima W; Geyer JT; Lee CS; Boiocchi L; Imahiyerobo AA; Orazi A; Bussel JB
Haematologica; 2014 May; 99(5):937-44. PubMed ID: 24463212
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.
Boiocchi L; Orazi A; Ghanima W; Arabadjief M; Bussel JB; Geyer JT
Mod Pathol; 2012 Jan; 25(1):65-74. PubMed ID: 21841770
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Brynes RK; Orazi A; Theodore D; Burgess P; Bailey CK; Thein MM; Bakshi KK
Am J Hematol; 2015 Jul; 90(7):598-601. PubMed ID: 25801698
[TBL] [Abstract][Full Text] [Related]
6. Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.
Ghanima W; Boiocchi L; Lee CS; Feng X; Geyer JT; Gudbrandsdottir S; Orazi A; Junker P; Bussel JB
Platelets; 2019; 30(2):222-228. PubMed ID: 29293383
[TBL] [Abstract][Full Text] [Related]
7. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Kuter DJ; Mufti GJ; Bain BJ; Hasserjian RP; Davis W; Rutstein M
Blood; 2009 Oct; 114(18):3748-56. PubMed ID: 19671919
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide study.
Ettrup MS; Jensen AØ; Engebjerg MC; Farkas DK; Nørgaard M; Cha S; Zhao S; Johansen P; Sørensen HT
Am J Hematol; 2010 Dec; 85(12):930-4. PubMed ID: 20981681
[TBL] [Abstract][Full Text] [Related]
10. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
11. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
Leung T; Lokan J; Turner P; Smith C
Pathology; 2011 Aug; 43(5):520-2. PubMed ID: 21753725
[No Abstract] [Full Text] [Related]
12. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
Nazy I; Kelton JG; Moore JC; Clare R; Horsewood P; Smith JW; Ivetic N; D'Souza V; Li N; Arnold DM
Br J Haematol; 2018 Apr; 181(2):234-241. PubMed ID: 29532903
[TBL] [Abstract][Full Text] [Related]
13. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
[TBL] [Abstract][Full Text] [Related]
15. Myelofibrosis in ITP and with TPO-RA - time to rethink?
Thachil J
Platelets; 2021 Oct; 32(7):995-996. PubMed ID: 32835570
[No Abstract] [Full Text] [Related]
16. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
Liebman HA; Pullarkat V
Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
Gernsheimer TB
Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
[TBL] [Abstract][Full Text] [Related]
18. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists.
Thachil J; Bagot C; Bradbury C; Cooper N; Lester W; Grainger JD; Lowe G; Evans G; Talks K; Sibson K; Garg M; Murphy MF; Watson HG; Bolton-Maggs PHB; Watson S; Scully M; Provan D; Newland A; Hill QA
Br J Haematol; 2018 Feb; 180(4):591-594. PubMed ID: 27879997
[No Abstract] [Full Text] [Related]
19. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.
Cantoni S; Carpenedo M; Mazzucconi MG; De Stefano V; Carrai V; Ruggeri M; Specchia G; Vianelli N; Pane F; Consoli U; Artoni A; Zaja F; D'adda M; Visentin A; Ferrara F; Barcellini W; Caramazza D; Baldacci E; Rossi E; Ricco A; Ciminello A; Rodeghiero F; Nichelatti M; Cairoli R
Am J Hematol; 2018 Jan; 93(1):58-64. PubMed ID: 28983953
[TBL] [Abstract][Full Text] [Related]
20. A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.
Brynes RK; Wong RS; Thein MM; Bakshi KK; Burgess P; Theodore D; Orazi A
Acta Haematol; 2017; 137(2):66-72. PubMed ID: 28006767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
